# High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

> **NCT07118670** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Edward Wood, MD** · enrollment: 40 (estimated)

## Conditions studied

- Proliferative Diabetic Retinopathy (PDR)

## Interventions

- **DRUG:** Aflibercept 8mg

## Key facts

- **NCT ID:** NCT07118670
- **Lead sponsor:** Edward Wood, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2028-02
- **Final completion:** 2028-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- Greater Houston Retina Research

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07118670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07118670, "High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07118670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*